Protara Therapeutics, based in New York, develops treatments for rare diseases and is conducting Phase II trials for its lead candidate, TARA-002, in non-muscle invasive bladder cancer and lymphatic malformations. The company also works on IV Choline Chloride for patients needing parenteral nutrition.
Richard S Levy bought 40,000 shares of TARA on 14 May at $3.19 per share, worth a total of $128K. They now own 51,000 TARA shares, or a 364% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
